Compare NQP & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NQP | CTKB |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.5M | 433.8M |
| IPO Year | N/A | 2021 |
| Metric | NQP | CTKB |
|---|---|---|
| Price | $12.10 | $4.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.88 |
| AVG Volume (30 Days) | 58.4K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $196,828,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.65 | $2.37 |
| 52 Week High | $11.89 | $7.30 |
| Indicator | NQP | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 47.20 |
| Support Level | $12.02 | $4.79 |
| Resistance Level | $12.18 | $5.16 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 45.00 | 9.57 |
Nuveen Pennsylvania Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal and Pennsylvania income taxes and to enhance portfolio value relative to the municipal bond market by investing in municipal securities that are exempt from federal, Pennsylvania state and local income taxes. It invests a majority of its assets in securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.